The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects
Open accessAbstract
Zoledronic acid (ZOL) is a nitrogen-containing bisphosphonate and its use in reducing osteoporosis and cancer-induced osteolysis is increasing. Recent findings indicated that ZOL has a direct effect on cancer cells. In this study, the effect of ZOL was examined on the aggressive MDA-MB-231 breast cancer cell line. ZOL induces an important inhibition of cell invasion at low concentrations (1 microM). This is not explained by modifications of proteases involved in cell invasiveness (matrix metalloproteinases and urokinase-type plasminogen activator), but by a disorganisation of actin cytoskeleton due to RhoA inhibition related to its defective prenylation as it was reversed by geranylgeraniol (GGOH) and mimicked by the Rho selective inhibitor C3 exoenzyme. In addition, ZOL inhibits the chemotactic effect induced by stromal cell-derived factor 1(SDF-1), a chemokine greatly involved in cancer metastasis to bone. This effect is related to both reduction of cell motility induced by RhoA inhibition and to a decreased expression of CXCR-4, the SDF-1 receptor. Finally, ZOL reduces Cox-2 expression and, consequently, the secretion of prostaglandins E2 (PGE2) in a RhoA-independent manner. This inhibition could contribute to bone protection in breast cancers because PGE2 stimulates osteoclast-mediated bone resorption. In summary, new insights in the mechanism of ZOL action on aggressive breast cancer cells are demonstrated and could explain its beneficial action in both the reduction of osteolysis and prevention of metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D., Golub, E., & Rodan, G. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115539 · Cited by 1,004
Cited by
Mevalonate pathway: A review of clinical and therapeutical implications
Buhaescu, I., & Izzedine, H. (2007) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2007.03.016 · Cited by 620
Terpene Biosynthesis: Modularity Rules
Oldfield, E., & Lin, F. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201103110 · Cited by 391
Organ selectivity in metastasis: regulation by chemokines and their receptors
Ben-Baruch, A. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9097-3 · Cited by 264
Transmigration: A New Property of Mature Multinucleated Osteoclasts
Saltel, F., Chabadel, A., Zhao, Y., Lafage-Proust, M.-H., Clézardin, P., Jurdic, P., & Bonnelye, E. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060821 · Cited by 41
Metadata
- Authors
- Denoyelle, C., Hong, L., Vannier, J.-P., Soria, J., & Soria, C.
- Venue
- British Journal of Cancer
- Published
- 2003-05
- Volume
- 88
- Issue
- 10
- Pages
- 1631-1640
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2084651782
- Cited by
- 158
- References
- 1
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. https://app.cochat.ai/papers/10.1038/sj.bjc.6600925
- The paper
- Denoyelle, C., Hong, L., Vannier, J.-P., Soria, J., & Soria, C. (2003). New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6600925
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.